Medtronic (Minneapolis) said it has scratched out a 4-3 vote at an FDA advisory panel to expand the indications for use for two of its electrophysiology devices, a piece of news that might take the edge off an otherwise difficult week for the firm. The panel's deliberations were girded by the Block HF trial, which found its way into the literature earlier this year, but the statement indicates only an expanded indication for patients with atrioventricular (AV) block and left ventricular (LV) systolic dysfunction, and does not address other proposed expansions of indications. Read More
